Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
An Extension Test of Whether to Use Oral Anti-anxiety Drugs (XANAX) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction
- Conditions
- OphthalmologyCataract Surgery AnesthesiaOral AnxiolyticSatisfaction Survey
- Interventions
- Other: Placebo Tablets
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06874452
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei,, Taiwan
Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety
- Conditions
- Oral AnxiolyticCataract SurgeryPhacoemulsificationSatisfaction SurveyState Anxiety
- Interventions
- Other: placebo tablets
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06826417
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Opioid Drug Interaction Study
- Conditions
- Drug InteractionsDrug Kinetics
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Shanna Babalonis, PhD
- Target Recruit Count
- 25
- Registration Number
- NCT06757140
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Detoxification From the Lipid Tract
- Conditions
- COVID-19 Vaccine Adverse Reaction
- Interventions
- Device: electroencephalogram biofeedbackDevice: electrical brain stimulationDevice: ultra-low frequency transcranial magnetic stimulation
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Pachankis, Yang I., M.D.
- Target Recruit Count
- 1
- Registration Number
- NCT06357104
- Locations
- 🇨🇳
Residential Address, Chongqing, Chongqing, China
Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor
- Conditions
- Essential Tremor
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 55
- Registration Number
- NCT06293638
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
- Conditions
- Abuse Potential
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT06097676
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Overland Park, Kansas, United States
A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 21
- Registration Number
- NCT05626439
- Locations
- 🇺🇸
Up0104 1001, Baltimore, Maryland, United States
A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 100
- Registration Number
- NCT05602818
- Locations
- 🇺🇸
Altasciences, Overland Park, Kansas, United States
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
- Conditions
- Stereotypical Prolonged Seizures
- Interventions
- Other: Placebo
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 350
- Registration Number
- NCT05077904
- Locations
- 🇯🇵
Ep0162 20316, Sapporo, Japan
🇯🇵Ep0162 20070, Shinjuku-ku, Japan
🇯🇵Ep0162 20297, Shinjuku-ku, Japan
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 300
- Registration Number
- NCT05076617
- Locations
- 🇺🇸
Ep0165 50511, Pittsburgh, Pennsylvania, United States
🇺🇸Ep0165 50491, Pittsburgh, Pennsylvania, United States
🇺🇸Ep0165 50513, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.